PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
5.43%
Revenue growth of 5.43% vs. zero growth in Medical - Pharmaceuticals. Walter Schloss might still want to see if it can translate into profits.
-1.29%
Negative gross profit growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would suspect poor product pricing or inefficient production.
1.44%
EBIT growth of 1.44% while Medical - Pharmaceuticals median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
-18.28%
Negative operating income growth while Medical - Pharmaceuticals median is -0.43%. Seth Klarman would check if structural or cyclical issues are at play.
5.98%
Net income growth of 5.98% while Medical - Pharmaceuticals median is zero. Walter Schloss might see potential if moderate gains can keep rising.
5.99%
EPS growth exceeding 1.5x Medical - Pharmaceuticals median of 2.45%. Joel Greenblatt would confirm if consistent earnings expansion underpins these gains.
5.99%
Diluted EPS growth exceeding 1.5x Medical - Pharmaceuticals median of 2.29%. Joel Greenblatt would confirm if strong net income growth or buybacks drive outperformance.
-0.00%
Share reduction while Medical - Pharmaceuticals median is 0.23%. Seth Klarman would see a relative advantage if others are diluting.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Dividend cuts while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see if others maintain or grow payouts, highlighting a relative weakness.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
14.31%
10Y revenue/share CAGR 1.25-1.5x Medical - Pharmaceuticals median of 10.08%. Mohnish Pabrai would see if consistent reinvestment or product expansions drive this gap.
2.26%
Below 50% of Medical - Pharmaceuticals median. Jim Chanos would suspect structural disadvantages or a higher share base limiting per-share growth.
-26.41%
Negative 3Y CAGR while Medical - Pharmaceuticals median is 1.36%. Seth Klarman would examine if the sector is otherwise stable, indicating a company-specific issue.
100.00%
OCF/share CAGR of 100.00% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest edge that can add up if momentum improves.
100.00%
OCF/share CAGR of 100.00% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
No Data
No Data available this quarter, please select a different quarter.
108.41%
Net income/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 43.89% over a decade. Joel Greenblatt might see a standout compounder of earnings.
54.75%
5Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 8.44%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
-17.52%
Negative 3Y CAGR while Medical - Pharmaceuticals median is 13.82%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
63.41%
Equity/share CAGR of 63.41% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
33.94%
5Y equity/share CAGR of 33.94% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
-10.40%
Negative 3Y equity/share growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.52%
Inventory growth of 7.52% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
6.64%
Asset growth of 6.64% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
3.81%
BV/share growth of 3.81% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
66.15%
Debt growth of 66.15% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest difference that matters if interest coverage is tight.
No Data
No Data available this quarter, please select a different quarter.
3.57%
SG&A growth of 3.57% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a modest overhead increase needing revenue justification.